PADOVA

Summary

The purpose of this study is to compare the effects of an experimental drug called prasinezumab in patients with early Parkinson's disease who are taking standard medication (either rasagiline, selegiline, or levodopa) to manage their disease symptoms. Participants will be randomly assigned to receive either prasinezumab or placebo (inactive substance). Prasinezumab is a type of medication called a monoclonal antibody. Prasinezumab may clear away harmful forms of a specific protein to prevent damage to brain cells, potentially slowing the course of Parkinson's disease.


Inclusion Criteria

  • Diagnosis of idiopathic PD based on MDS criteria with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity), without any other known or suspected cause of parkinsonism
  • On symptomatic PD medication, with stable doses for at least 3 months prior to baseline
  • A diagnosis of PD for at least 3 months to maximum 3 years at screening
  • MDS-UPDRS Part IV score of 0 at screening and prior to randomization

Study Location(s)

Beverly

More about this Clinical Trial

Full Title

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Intravenous Prasinezumab In Participants With Early Parkinson's Disease

Details
Disease Type/Condition

Parkinson's Disease

Principal Investigator

Tagliati, Michele

Age Group

Adult

Phase

II

IRB Number

STUDY00001346

ClinicalTrials.gov ID
NCT04777331
Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Parkinson's Disease

Principal Investigator

Tagliati, Michele

Age Group

Adult

Phase

II

IRB Number

BN42358

ClinicalTrials.gov ID

NCT04777331

Key Eligibility
ClinicalTrials.gov
Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?